On May 29, Johnson & Johnson announced itsFirst-in-Class SelectivityHuman Orexin2Receptor (OX2R) AntagonistSeltorexant（JNJ-42847922) Adjunctive Treatment for Patients with Major Depressive Disorder (MDD)Phase III MDD3001 Study Met All Primary and Secondary Endpoints.This study is a randomized, double-blind, multi-center, placebo-controlled clinical trial (n=550) that evaluatedSEfficacy and Safety of Eltorexant (20mg, Once Daily) versus Placebo as an Adjunctive Treatment in Adult and Elderly MDD Patients with Inadequate Response to Antidepressants and Insomnia Symptoms. The primary endpoint of the study is Day 43 for patients.Change in the total score of the Montgomery-Asberg Depression Rating Scale (MADRS) from baseline.
The results showed,SeltorexantThe MADRS total score of the group significantly decreased compared to the placebo group, with statistically and clinically significant data. Moreover, sleep disturbance outcomes improved in patients who had previously shown an inadequate response to selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors (SSRI/SNRI).In addition，Seltorexant has good safety andTolerance, itsCommon Adverse Event Incidence Rate vs. Placebo GroupSimilar。Detailed research results will be announced at the upcoming American Society of Clinical Psychopharmacology (ASCP) meeting.MDD is often accompanied by sleep disorders, such as insomnia or hypersomnia. Approximately 60% of patients with MDD continue to experience insomnia symptoms after receiving standard oral antidepressant treatment. Currently, there is no therapy approved for the treatment of MDD with insomnia symptoms.Johnson & Johnson has developed several new drugs for MDD, includingRight Chloramine Ketone (Trade Name:Spravato) has been approved for marketing,Seltorexant andAticaprantThe progress is closely following, while other products are still in the early or middle stages.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
↑Click to scan the QR code and go directly to the live broadcast room↑
